TABLE 1-continued

Ex #	Structure	Chemical Name	ESMS +m/z	IC_{50} (uM)
534		1-({[5-(3,4-difluorophenyl)-3-({[(2,4,6-trimethylphenyl)amino]carbonyl}amino)-2-thienyl]carbonyl}amino)cyclohexanecarboxylic acid	542 (M + H)	0.104
535		1-({[5-(3,4,5-trifluorophenyl)-3-({[(2,4,6-trimethylphenyl)amino]carbonyl}amino)-2-thienyl]carbonyl}amino)cyclohexanecarboxylic acid	560 (M + H)	0.206

What is claimed is:

1. A compound of Formula 1 comprising:

Formula 1



a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof

wherein:

A is C(=O)NQ^{3}Q^4 or C(=O)OH;

Q^1 and Q^2 are fused together;

Q^1 is selected from the group consisting of (i) a 5- or 6-membered aromatic ring, (ii) a 5- or 6-membered cycloalkyl ring, (iii) a 5- or 6-membered heteroaromatic ring having at least one heteroatom selected from the group consisting of nitrogen, oxygen, or sulfur, and (iv) a 4- to 8-membered heterocyclic ring having at least one heteroatom selected from the group consisting of nitrogen, oxygen, or sulfur; and q is 0 or 1;

Q^2 is selected from the group consisting of (i) a 5- or 6-membered aromatic ring and (ii) a 5- or 6-membered heteroaromatic ring having at least one heteroatom selected from the group consisting of nitrogen, oxygen, or sulfur;

R^1 and R^2 are each independently selected from the group consisting of hydrogen, C_{1-6} alkyl, halo, alkoxy, monoalkylamino, and dialkylamino;

R^3 is hydrogen or a C_{1-6} alkyl;

Q^3 and Q^4 are each independently selected from the group consisting of (i) hydrogen, (ii) C_{1-6} alkyl, (iii) —CR^{4}R^{5}Z, where Z is a 5- or 6-membered heteroaryl having at least one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur, (iv) aryl, and (v) —CR^{4}R^{5}COOH;